Inflammation and psychomotor retardation in depression: The moderating role of glymphatic system

Qunjun Liang1, Bo Peng2, Shengli Chen3

  • 1Department of Medical Imaging, Shenzhen Nanshan People's Hospital, Shenzhen University, Shenzhen 518000, People's Republic of China; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen 518060, People's Republic of China.

PubMed
Abstract

Insights

Impaired brain waste clearance (glymphatic system) worsens inflammation-linked psychomotor retardation in major depressive disorder. Improving glymphatic system function may offer a therapeutic strategy for MDD.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Immunology

Background:

  • Psychomotor retardation (PMR) is a key symptom in major depressive disorder (MDD).
  • The link between inflammation and PMR is debated.
  • The glymphatic system (GS) interacts with the brain's immune system.

Purpose of the Study:

  • To investigate if glymphatic system function moderates the relationship between inflammation and PMR in MDD patients.
  • To explore the role of GS in inflammation-related changes in the motor circuit.

Main Methods:

  • 67 MDD patients and 67 healthy controls (HCs) underwent MRI.
  • Assessed PMR, inflammation (hsCRP), and GS function using diffusion tensor imaging.
  • Analyzed functional connectivity (FC) and morphology within the motor circuit.

Main Results:

  • GS function was impaired in MDD patients compared to HCs.
  • Inflammation (hsCRP) aggravated PMR severity more in individuals with low GS function.
  • GS function moderated inflammation-related alterations in motor cortex morphology and FC.

Conclusions:

  • A well-functioning GS mitigates inflammation-induced PMR and protects against inflammatory damage.
  • GS function plays a crucial role in MDD psychopathology.
  • Targeting GS function presents a potential therapeutic avenue for MDD.